account_id none on file
legal_name Zenas BioPharma, Inc.
ticker ZBIO
cik 1953926
domain zenasbio.com
linkedin_company_url https://www.linkedin.com/company/zenas-biopharma/
entry_point_account_id none on file
name Zenas BioPharma Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 0 family 0
why_nownone on file
callsnone on file
filings
● costs of outside consultants, including their fees, stock-based compensation and related travel expenses. 36 Table of Contents We expense research and development costs as incurred.
filing / Aug 13, 2026 / receipt
● a $6.2 million increase in personnel costs, including a $4.3 million increase in salary and benefit related expense, due to an increase in headcount, a $1.7 million increase in stock-based compensation expense, and a $0.2 million increase in external contractor expenses and other personnel costs.
filing / Aug 13, 2026 / receipt
● a $2.3 million increase in personnel costs, including a $1.7 million increase in salary and benefit related expense, primarily due to an increase in headcount to support pre-commercialization efforts, a $0.8 million increase in stock-based compensation expense, offset by a $0.1 million decrease in external contractor expense and other personnel costs, and a $0.1 million decrease in recruiting expense; and
filing / Aug 13, 2026 / receipt
Transition of Chief Financial Officer and Chief Business Officer to Strategic Advisor to the Chairman of the Board Jennifer Fox will be transitioning from her role as the Company’s Chief Financial Officer and Chief Business Officer effective as of September 30, 2026 after which she will be a Strategic Advisor to the Chairman of the Board, first as an employee and then, as of July 1, 2027, as a consultant pursuant t
filing / Aug 13, 2026 / receipt
Jennifer Fox will be transitioning from her role as the Company’s Chief Financial Officer and Chief Business Officer effective as of September 30, 2026 after which she will be a Strategic Advisor to the Chairman of the Board, first as an employee and then, as of July 1, 2027, as a consultant pursuant to a consulting agreement.
filing / Aug 13, 2026 / receipt
● costs of outside consultants, including their fees, stock-based compensation and related travel expenses. We expense research and development costs as incurred.
filing / May 13, 2026 / receipt
These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, among other expenses.
filing / May 13, 2026 / receipt
● a $5.8 million increase in personnel costs, including a $3.9 million increase in salary and benefit related expense, due to an increase in headcount, a $1.5 million increase in stock-based compensation expense, and a $0.4 million increase in external contractor expenses and other personnel costs.
filing / May 13, 2026 / receipt
executivesnone on file
familynone on file
upcomingnone on file
changesnone on file
mcp_package_hint
slug zenas-biopharma-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$